Tarsus Pharmaceuticals (TARS) Other Non Operating Income (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Other Non Operating Income of -$87000.0 for Q1 2026, down 7.41% year-over-year from -$93960.0 in Q1 2025, and down 167.97% quarter-over-quarter from $128000.0 in Q4 2025.
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) Other Non Operating Income (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Other Non Operating Income history runs 7 years deep, the most recent figure standing at -$87000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 7.41% year-over-year to -$87000.0; the TTM figure through Mar 2026 stood at $139000.0 (up 236.27% YoY), while the FY2024 annual figure was -$1.9 million, down 793.43% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$87000.0, down from $128000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $309000.0 in Q4 2023, with the low at -$637000.0 in Q4 2022.
- The 5-year median for Other Non Operating Income is -$7000.0 (2022), against an average of -$47400.0.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income slumped 3116.67% in 2024, then jumped 190.91% in 2025.
- Tarsus Pharmaceuticals' Other Non Operating Income stood at -$637000.0 in 2022, then surged by 148.51% to $309000.0 in 2023, then sank by 85.76% to $44000.0 in 2024, then surged by 190.91% to $128000.0 in 2025, then sank by 167.97% to -$87000.0 in 2026.
- Business Quant data shows TARS's Other Non Operating Income at -$87000.0 in Q1 2026, $128000.0 in Q4 2025, and $98000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Tarsus Pharmaceuticals | 3.96 Bn | 3.51 Bn | 161.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -281,000.00 |
| Mar 31, 2026 | -87,000.00 |
| Dec 31, 2025 | -74,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Jun 30, 2025 | -145,000.00 |
| Mar 31, 2025 | -81,000.00 |
| Sep 30, 2024 | 67,000.00 |
| Jun 30, 2024 | -1.94 Mn |
| Mar 31, 2024 | -181,000.00 |
| Dec 31, 2023 | 363,000.00 |
| Sep 30, 2023 | -48,000.00 |
| Jun 30, 2023 | -47,000.00 |
| Mar 31, 2023 | -17,000.00 |
| Dec 31, 2022 | 19,000.00 |
| Sep 30, 2022 | -18,000.00 |
| Jun 30, 2022 | -257,000.00 |
| Mar 31, 2022 | -245,000.00 |
| Dec 31, 2021 | 235,000.00 |
| Sep 30, 2021 | -346,000.00 |
| Jun 30, 2021 | -876,000.00 |